Citadel Advisors
INDV icon

Citadel Advisors’s Indivior Pharmaceuticals INDV Stock Holding History

Citadel Advisors’s Portfolio INDV Stock Details INDV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.75M Buy
57,400
+32,000
+126% +$1.06M ﹤0.01% 6375
2025
Q4 		$911K Buy
25,400
+8,800
+53% +$269K ﹤0.01% 7599
2025
Q3 		$400K Buy
16,600
+4,000
+32% +$83.7K ﹤0.01% 9671
2025
Q2 		$186K Buy
12,600
+6,900
+121% +$80.4K ﹤0.01% 10745
2025
Q1 		$54.3K Buy
5,700
+300
+6% +$3.15K ﹤0.01% 12233
2024
Q4 		$67.1K Buy
5,400
+3,800
+238% +$39.1K ﹤0.01% 12035
2024
Q3 		$15.6K Sell
1,600
-14,200
-90% -$166K ﹤0.01% 12961
2024
Q2 		$255K Buy
15,800
+15,700
+15,700% +$283K ﹤0.01% 9456
2024
Q1 		$2.14K Buy
+100
New +$1.88K ﹤0.01% 14039

Other funds holding INDV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
OCM
Oaktree Capital Management Los Angeles, California $6.56B AUM 42.97% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citadel Advisors's INDV Position: Q1 2026 in Review

Citadel Advisors increased its Indivior Pharmaceuticals (INDV) stake by 17% in Q1 2026, buying an estimated $16.9M and bringing the position to 3,574,044 shares worth $109M. The position accounts for 0.02% of the portfolio, ranked #755.

Citadel Advisors first reported a position in INDV in Q1 2024 and has held it in 9 quarters since. The position peaked at $110M in Q4 2025. 289 funds tracked by Wall St. Rank hold INDV as of Q1 2026.

  • Citadel Advisors held 3,574,044 shares of Indivior Pharmaceuticals worth $109M as of Q1 2026.
  • Citadel Advisors bought 512,142 Indivior Pharmaceuticals shares in Q1 2026, an estimated $16.9M.
  • Indivior Pharmaceuticals made up 0.02% of Citadel Advisors's portfolio in Q1 2026, its #755 holding.
  • Citadel Advisors first reported a position in Indivior Pharmaceuticals in Q1 2024 and has held it in 9 quarters since.
  • Citadel Advisors's Indivior Pharmaceuticals position peaked at $110M in Q4 2025.
  • 289 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.